Wnt Scientific is a preclinical stage company developing the therapeutics for joint diseases. The lead products are StemGel for osteoarthritis and TenGel for tendon injury. The products showed robust efficacy in animal studies. The MOA of StemGel is to inject a protein that specifically inhibits Wnt signaling to the joint cavity to suppress inflammation and stimulate cartilage regeneration. We have developed the CHO cell line to scale-up the peptide production. TenGel is the small molecules encapsulated in hydrogel that is topically used to the tendon tear site to stimulate tendon stem cell proliferation and differentiation. For TenGel, we have demonstrated the safety profile and investigated the pK of the APIs. The company also developed a pipeline for nonunion fracture and critical size bone defect repair.